Immunotherapy plus chemo shows promise for tough uterine cancer
NCT ID NCT07108270
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether the immunotherapy drug dostarlimab, given together with standard chemotherapy (carboplatin and paclitaxel), can help Chinese patients with a specific genetic type of advanced or recurrent endometrial cancer. The study will enroll 30 participants and measure how many have a lasting response for at least 12 months. The goal is to find a more effective treatment for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dostarlimab (an immunotherapy drug) combined with chemotherapy drugs carboplatin and paclitaxel
What this could lead to
If successful, this could offer a new treatment option for Chinese patients with a specific type of advanced or recurrent endometrial cancer.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination therapy may cause side effects like immune reactions or typical chemo toxicities.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGJinan, Shandong, 250117, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••